New drug M701 aims to stop Cancer-Related fluid buildup without drains

NCT ID NCT06266091

Completed Symptom relief Sponsor: Wuhan YZY Biopharma Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a drug called M701, given directly into the belly, combined with standard cancer therapy, for people with malignant ascites (fluid buildup) from stomach, colon, or ovarian cancer. The goal was to see if M701 could delay the need for fluid drainage and improve survival. 115 participants were enrolled in this Phase 2 trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: M701
What this could lead to: If successful, this could provide a new way to control malignant ascites, reducing the need for repeated drainage procedures and improving quality of life.
What could go wrong: This is a Phase 2 trial with only 115 participants, so results may not be definitive. The drug may not work better than standard drainage, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer fallopian tube carcinoma gastric cancer ovarian cancer primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT ASCITES

Contacts and locations

Locations

The First Medical Center of Chinese PLA General Hospital

Beijing, Beijing Municipality, 100141, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.